Journal of Antimicrobial Chemotherapy · 2022 · 13 citations · 6 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAcquired ResistanceAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsCarbapenem ResistanceMechanisms Of Antimicrobial ResistanceAntibiotic Resistance In Bloodstream IsolatesAntimicrobial Susceptibility Testing CorrelatesCarbapenem-resistant EnterobacteralesEnterobacterales ResistanceKlebsiella Pneumoniae ResistanceMortality RatesResistance ReversionSubpopulation Dynamics
Infections with carbapenem-resistant Enterobacterales (CRE) are associated with mortality rates of up to 50% in the USA.1 Optimal empirical treatment remains challenging and requires collaboration between microbiologists, clinicians and sometimes translational researchers as traditional susceptibility testing methods may fail to detect clinically meaningful resistance. Here we describe a patient with Klebsiella pneumoniae bloodstream infection where heteroresistance to cefiderocol may have contributed to clinical failure despite seemingly appropriate antimicrobial therapy. Heteroresistance is a phenomenon whereby an established minority subpopulation of resistant bacteria within the larger community proliferates under specific antibiotic pressure. These subpopulations are often infrequent enough that they are not detected using standard antimicrobial susceptibility testing. After prolonged exposure to the specific antibiotic, the resistant subpopulation expands, and clinically meaningful resistance can occur. Transient and unstable gene amplification or mutations that revert if antibiotic pressure is withdrawn may drive the resistant subpopulation.2 Recently, cefiderocol heteroresistance has been reported in CRE, but the clinical implications are unresolved.3 Our findings raise concern that the increased mortality observed with cefiderocol use in trials such as CREDIBLE-CR might be attributed to undetected heteroresistance despite reported susceptibility using conventional testing.3
6
Gopi Patel, Shirish Huprikar, Stephanie H. Factor et al. · Infection Control and Hospital Epidemiology · 2008 · 838 citations
Life Sciences, Infectious Diseases, Antimicrobial Resistance +14
Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 792 citations
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2020 · 427 citations
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2021 · 392 citations · Full text
Steven H. Marshall, Andrea M. Hujer, Laura J. Rojas et al. · Antimicrobial Agents and Chemotherapy · 2017 · 287 citations · Full text